Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Leuprolide Acetate

FDA-approved product (solution, subcutaneous), marketed as Eligard Kit, Fensolvi Kit, Leuprolide Acetate and 8 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Leuprolide Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Central precocious puberty
  • Metastatic prostate cancer
  • Neoplasm
  • Precocious puberty
  • Prostate adenocarcinoma
  • Prostate cancer
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Gonadotropin releasing hormone analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA59.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli59.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Leuprolide Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Leuprolide Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

    NCT07596212 · start 2026-09

    Registered record
    Registry ID
    NCT07596212
    Conditions
    Early-stage Breast Cancer; Hypoactive Sexual Desire Disorder; Hormone Receptor Positive Breast Carcinoma; Breast Cancer
    Interventions
    Aromatase Inhibitors; Bupropion; GnRH agonist
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-09
    Completion
    2031-09
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEarly-stage Breast Cancer; Hypoactive Sexual Desire Disorder; Hormone Receptor Positive Breast Carcinoma; Breast Cancer
    InterventionAromatase Inhibitors; Bupropion; GnRH agonist
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty

    NCT06926933 · start 2024-12-12

    Registered record
    Registry ID
    NCT06926933
    Conditions
    CPP
    Interventions
    Eligard® 45 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2024-12-12
    Completion
    2027-11-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCPP
    InterventionEligard® 45 mg
    PhasePhase 4
    Registry statusActive not recruiting

  • Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer

    NCT06490328 · start 2024-05-30

    Registered record
    Registry ID
    NCT06490328
    Conditions
    Advanced Prostate Cancer
    Interventions
    DKF-MA102
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2024-05-30
    Completion
    2026-03-09
    Enrolment
    161

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Prostate Cancer
    InterventionDKF-MA102
    PhasePhase 3
    Registry statusCompleted

  • A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer

    NCT06394804 · start 2024-04-29

    Registered record
    Registry ID
    NCT06394804
    Conditions
    Low-Grade Serous Ovarian Cancer
    Interventions
    Avutometinib; Defactinib; Letrozole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-04-29
    Completion
    2027-04
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLow-Grade Serous Ovarian Cancer
    InterventionAvutometinib; Defactinib; Letrozole
    PhasePhase 2
    Registry statusRecruiting

  • Surgery and ART For Endometrioma

    NCT03717870 · start 2023-10

    Registered record
    Registry ID
    NCT03717870
    Conditions
    Ovarian Endometrioma; Infertility, Female
    Interventions
    Laparoscopic enucleation of ovarian endometrioma.; Prolonged pituitary downregulation; Assisted Reproductive Technology (ART)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2023-10
    Completion
    2027-10
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Endometrioma; Infertility, Female
    InterventionLaparoscopic enucleation of ovarian endometrioma.; Prolonged pituitary downregulation; Assisted Reproductive Technology (ART)
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Evaluate the Efficacy and Safety of DWJ108J

    NCT06025409 · start 2023-08-01

    Registered record
    Registry ID
    NCT06025409
    Conditions
    Central Precocious Puberty
    Interventions
    Leuprolide Acetate 11.25 MG/ML
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2023-08-01
    Completion
    2025-08-31
    Enrolment
    79

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCentral Precocious Puberty
    InterventionLeuprolide Acetate 11.25 MG/ML
    PhasePhase 3
    Registry statusUnknown

  • Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624

    NCT05781217 · start 2023-03-14

    Registered record
    Registry ID
    NCT05781217
    Conditions
    Prostate Cancer; Salvage Radiotherapy; Biochemical Recurrence; Androgen Deprivation Therapy; Metastases-free Survival
    Interventions
    triptorelin, goserelin, leuprorelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-03-14
    Completion
    2032-12
    Enrolment
    534

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Salvage Radiotherapy; Biochemical Recurrence; Androgen Deprivation Therapy +1 more
    Interventiontriptorelin, goserelin, leuprorelin
    PhasePhase 3
    Registry statusRecruiting

  • A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty

    NCT05341115 · start 2023-03-12

    Registered record
    Registry ID
    NCT05341115
    Conditions
    Central Precocious Puberty
    Interventions
    Leuprorelin Acetate Depot 3M
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-03-12
    Completion
    2025-03-10
    Enrolment
    79

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCentral Precocious Puberty
    InterventionLeuprorelin Acetate Depot 3M
    PhasePhase 4
    Registry statusCompleted

  • Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

    NCT05498272 · start 2023-02-01

    Registered record
    Registry ID
    NCT05498272
    Conditions
    Prostate Cancer; BRCA1 Mutation; BRCA2 Mutation; Prostatic Adenocarcinoma; High-Risk Cancer
    Interventions
    Olaparib; LHRH agonist
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-02-01
    Completion
    2026-12
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; BRCA1 Mutation; BRCA2 Mutation; Prostatic Adenocarcinoma +1 more
    InterventionOlaparib; LHRH agonist
    PhasePhase 2
    Registry statusActive not recruiting

  • Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

    NCT05605964 · start 2023-01-28

    Registered record
    Registry ID
    NCT05605964
    Conditions
    Prostate Cancer
    Interventions
    Relugolix; Leuprolide Acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-01-28
    Completion
    2024-12-31
    Enrolment
    387

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionRelugolix; Leuprolide Acetate
    PhasePhase 3
    Registry statusCompleted

  • A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

    NCT04961996 · start 2021-08-27

    Registered record
    Registry ID
    NCT04961996
    Conditions
    Early Breast Cancer
    Interventions
    Giredestrant; Physician's Choice of Endocrine Therapy; LHRH Agonist
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-08-27
    Completion
    2033-09-30
    Enrolment
    4,170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEarly Breast Cancer
    InterventionGiredestrant; Physician's Choice of Endocrine Therapy; LHRH Agonist
    PhasePhase 3
    Registry statusActive not recruiting

  • Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW

    NCT04760691 · start 2021-03-01

    Registered record
    Registry ID
    NCT04760691
    Conditions
    HIV; Prophylaxis; Transgender
    Interventions
    Truvada alone; Truvada plus Leuprolide 11.25mg intramuscular injection; Truvada plus Estradiol 1 mg; Truvada plus Estradiol 6 mg; Estradiol 6 mg alone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-03-01
    Completion
    2025-03-24
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Prophylaxis; Transgender
    InterventionTruvada alone; Truvada plus Leuprolide 11.25mg intramuscular injection; Truvada plus Estradiol 1 mg; Truvada plus Estradiol 6 mg +1 more
    PhasePhase 1
    Registry statusCompleted

  • Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

    NCT04513717 · start 2021-01-21

    Registered record
    Registry ID
    NCT04513717
    Conditions
    Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
    Interventions
    Apalutamide; Bicalutamide; Biospecimen Collection; Bone Scan; Buserelin; Computed Tomography; Degarelix; Flutamide; Goserelin; Histrelin; Leuprolide; Magnetic Resonance Elastography; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration; Radiation Therapy; Relugolix; Triptorelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-01-21
    Completion
    2038-12-31
    Enrolment
    2,753

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
    InterventionApalutamide; Bicalutamide; Biospecimen Collection; Bone Scan +14 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Modified Downregulation for Women With Adenomyosis of the Uterus Prior to Frozen-thawed Embryo Transfer.

    NCT03946722 · start 2020-08-17

    Registered record
    Registry ID
    NCT03946722
    Conditions
    Adenomyosis
    Interventions
    GnRH analogue downregulation; Participant questionnaire
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-08-17
    Completion
    2024-05-17
    Enrolment
    162

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenomyosis
    InterventionGnRH analogue downregulation; Participant questionnaire
    PhasePhase 4
    Registry statusUnknown

  • Neurobiology of Bulimia Nervosa

    NCT04225221 · start 2020-02-24

    Registered record
    Registry ID
    NCT04225221
    Conditions
    Bulimia Nervosa
    Interventions
    Estradiol; Micronized progesterone; Leuprolide Acetate; Placebo Oral Capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-02-24
    Completion
    2022-04-04
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBulimia Nervosa
    InterventionEstradiol; Micronized progesterone; Leuprolide Acetate; Placebo Oral Capsule
    PhasePhase 2
    Registry statusCompleted